Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone and bone

C Ohlsson1, B A Bengtsson, O G Isaksson

  • 1Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden. Claes@SS.GU.SE

Endocrine Reviews
|March 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

Technological readiness and implementation of genomic-driven precision medicine for complex diseases.

Journal of internal medicine·2021
Same author

Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

High platelet count is associated with low bone mineral density: The MrOS Sweden cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Interleukin 17A: a Janus-faced regulator of osteoporosis.

Scientific reports·2020

Growth hormone (GH) influences bone metabolism by stimulating both bone resorption and formation, leading to a biphasic effect on bone mass. Long-term GH treatment in adults with GH deficiency eventually increases bone mass.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Metabolic Regulation

Background:

  • Growth hormone (GH) is crucial for longitudinal bone growth.
  • Recent studies reveal GH's significant role in regulating human bone metabolism, impacting both bone formation and resorption.
  • GH exerts its effects directly on osteoblasts and indirectly via insulin-like growth factor-I (IGF-I).

Purpose of the Study:

  • To elucidate the complex cellular effects of GH on bone remodeling.
  • To present a biphasic model for GH action in bone metabolism.
  • To discuss potential therapeutic strategies targeting the GH/IGF-I axis for bone health.

Main Methods:

  • Review of in vivo and in vitro studies on GH's effects on bone cells.
  • Analysis of clinical data from Growth Hormone Deficiency (GHD) patients undergoing GH treatment.

Related Experiment Videos

  • Presentation of simplified models illustrating GH's cellular effects and biphasic action on bone remodeling.

    • Main Results:

    • GH increases bone formation via direct osteoblast interaction and IGF-I induction.
    • GH also stimulates bone resorption, with potential regulation of osteoclast formation.
    • GH treatment in GHD adults shows a biphasic effect: initial resorption followed by increased formation, leading to net bone mass gain after 12-18 months.

    Conclusions:

    • GH has a dual role in bone remodeling, initially increasing resorption and subsequently enhancing formation.
    • A biphasic model is proposed, where initial bone loss is followed by a net gain in bone mass.
    • Therapeutic strategies may involve GH, IGF, or GH-releasing factors to modulate the GH/IGF-I axis for bone health.